
[TOP STORY] Will debt-laden Ascendis have to sell its crown jewel?
Loading player...
‘Blantyre and L1 Health have just added to the cocktail of what Ascendis could potentially become in the next 12 to 18 months’: Small-cap analyst Anthony Clarke.

